Fibrocell Science

Delivering Gene Therapy for Rare Skin Disorders
Our ECC with Fibrocell Science, Inc. (NYSE MKT: FCSC), a biotechnology company commercializing fibroblasts for therapeutic applications, aims to identify the optimal genetic program to deliver a therapy for patients with a rare and devastating skin disorder that currently has no treatment or cure.
Lead Program
We are currently working with Fibrocell to explore treatments for recessive dystrophic epidermolysis bullosa (RDEB), a rare, genetically-based skin blistering disorder. RDEB is an autosomal recessive disorder characterized by the loss of collagen type VII, an important protein component of the anchoring fibers that connect the dermis to the epidermis. Our proposed treatment for this disease will provide autologous, gene-modified fibroblasts that will produce collagen VII in vivo.
LAVIV® (azficel-T)
Our cell biologists and process engineers are working with Fibrocell to improve the process efficiency and cost of goods related to the manufacture of of LAVIV® (azficel-T), Fibrocell’s autologous cellular product indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles (“smile” or “laugh” lines) in adults.
New Projects
We expanded the scope of the ECC with Fibrocell to include treatments based on engineered autologous fibroblast cells for the localized treatment of autoimmune and inflammatory disorders including morphea (localized scleroderma), cutaneous eosinophilias and moderate to severe psoriasis.
Learn more about Fibrocell Science.

In the News